Taken together, these data show that exosome-bound PD-L1 inhibits T-cells both in the tumor bed and at a distance from the tumor (lymph nodes, spleen) and, through these effects, contributes to tumor progression and resistance toward immunotherapy. Here, CD274 is linked to neoplasm.